CN103479824A - Traditional Chinese medicine compound for treating chronic periodontitis and gastritis and preparation method thereof - Google Patents
Traditional Chinese medicine compound for treating chronic periodontitis and gastritis and preparation method thereof Download PDFInfo
- Publication number
- CN103479824A CN103479824A CN201310425402.1A CN201310425402A CN103479824A CN 103479824 A CN103479824 A CN 103479824A CN 201310425402 A CN201310425402 A CN 201310425402A CN 103479824 A CN103479824 A CN 103479824A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- active component
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 201000001245 periodontitis Diseases 0.000 title claims abstract description 32
- 208000007882 Gastritis Diseases 0.000 title claims abstract description 26
- 208000001277 chronic periodontitis Diseases 0.000 title claims abstract description 25
- 208000023652 chronic gastritis Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 title abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 82
- 239000000203 mixture Substances 0.000 claims description 36
- 241000218176 Corydalis Species 0.000 claims description 34
- 239000012567 medical material Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 241000208340 Araliaceae Species 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 18
- 241000222336 Ganoderma Species 0.000 claims description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 17
- 235000008434 ginseng Nutrition 0.000 claims description 17
- 241000005787 Cistanche Species 0.000 claims description 16
- 241000190633 Cordyceps Species 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 241000725145 Homalomena Species 0.000 claims description 10
- 241001038563 Pseudostellaria Species 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000019634 flavors Nutrition 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 238000005325 percolation Methods 0.000 claims description 7
- -1 filters Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 22
- 244000307697 Agrimonia eupatoria Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 241000218671 Ephedra Species 0.000 abstract 1
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 241001598107 Imperata Species 0.000 abstract 1
- 241000123069 Ocyurus chrysurus Species 0.000 abstract 1
- 235000012874 Phaseolus calcaratus Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 240000006688 Telosma cordata Species 0.000 abstract 1
- 235000017352 Telosma cordata Nutrition 0.000 abstract 1
- 240000001417 Vigna umbellata Species 0.000 abstract 1
- 235000011453 Vigna umbellata Nutrition 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 235000000125 common agrimony Nutrition 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 26
- 210000002784 stomach Anatomy 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 18
- 230000036407 pain Effects 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000008187 granular material Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000002775 capsule Substances 0.000 description 11
- 239000006188 syrup Substances 0.000 description 10
- 235000020357 syrup Nutrition 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000004195 gingiva Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
- 229960000282 metronidazole Drugs 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 206010018275 Gingival atrophy Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000005888 Periodontal Pocket Diseases 0.000 description 3
- 206010067171 Regurgitation Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000004596 appetite loss Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 201000005562 gingival recession Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010018276 Gingival bleeding Diseases 0.000 description 2
- 208000024283 Gingival haemorrhages Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 208000006766 bile reflux Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 238000002575 gastroscopy Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000015091 medicinal tea Nutrition 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007119 pathological manifestation Effects 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960000620 ranitidine Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 208000002310 Achlorhydria Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- MQGKFAGKLNYJRE-UHFFFAOYSA-N Anhydroalkannin Natural products CC(=CC=CC1=CC(=O)c2c(O)ccc(O)c2C1=O)C MQGKFAGKLNYJRE-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 241000336291 Cistanche deserticola Species 0.000 description 1
- 241000336316 Cistanche tubulosa Species 0.000 description 1
- 241000221751 Claviceps purpurea Species 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000783421 Corydalis saxicola Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 241000506964 Dichondra repens Species 0.000 description 1
- 241000876833 Emberizinae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034619 Gingival inflammation Diseases 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000130660 Hepialidae Species 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000123866 Homalomena occulta Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XLBIBBZXLMYSFF-UHFFFAOYSA-M Propantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 XLBIBBZXLMYSFF-UHFFFAOYSA-M 0.000 description 1
- 241001038562 Pseudostellaria heterophylla Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000000661 Rosa laevigata Nutrition 0.000 description 1
- 241001278833 Rosa laevigata Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229940099209 probanthine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a traditional Chinese medicine compound for treating chronic periodontitis and gastritis and a preparation method of the traditional Chinese medicine compound for treating the chronic periodontitis and the gastritis. The traditional Chinese medicine compound is prepared from ephedra, fructus forsythia, phaseolus calcaratus, honeysuckle, dandelion, Chinese violet, lalang grass rhizome, madder roots and hairyvein agrimony by weight. The traditional Chinese medicine compound is suitable for acute nephritis caused by inward return of heat toxin and accumulation of damp and heat. The traditional Chinese medicine compound is definite in curative effect and better in effect than the prior art in the respect of treating the chronic periodontitis and the gastritis.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of Chinese medicine composition for the treatment of chronic periodontitis and gastritis and preparation method thereof.
Background technology
Periodontitis has the title of " gingival atrophy ", " tooth root a surname reveal " at the classic books of the traditional Chinese medical science.Traditional Chinese Medicine is divided into deficiency syndrome and the large class of excess syndrome two by periodontitis.Excess syndrome generally shows as the acute inflammations such as red swelling of gingiva, pain, hemorrhage, pyorrhea, and whole body can have heating, leucocytosis, and constipation with dry stool, yellow fur is thick etc., how by due to stomach-fire.Deficient syndrome is the gingiva mild pain, and the periodontal pyorrhea is rare, few, masticatory atonia, simultaneously with dizziness, tinnitus, insomnia, feverish sensation in the palms and soles or be afraid of cold, the performance of the chronic periodontitis such as weak.But heat clearing away of excess syndrome, removing toxic substances, pathogenic fire purging, deficiency syndrome can be tonified Qi of the kidney, the warming the spleen the kidney invigorating.The Primary Care of tradition periodontitis is to reach by removing local paathogenic factor the purpose of controlling the periodontitis progress, is the most basic effective means of sound of baby talk week treatment.Use the hibitane broad ectrum antibiotic to be combined with sialoglycoprotein, the facing adhesion protein is reduced, disturb bacterial plaque to form, reach the purpose of preventing and reducing periodontal disease and dental caries.But use such western medicine periodontal disease can only reach the purpose of temporarily taking stopgap measures, disease is outbreak repeatedly easily.
Therefore, it is main that the treatment chronic periodontitis is worked as the warming the spleen the kidney invigorating, and from inside to outside, empty inflammation disappears to the greatest extent and could effect a radical cure no longer recurrence.
Chronic gastritis is modal gastropathy, belongs to the sick categories such as Chinese medicine " gastric abscess ", " feeling of fullness ", " acid regurgitation ", " noisy ", " indigestion and loss of appetite ".The traditional Chinese medical science thinks, chronic gastritis many because of long-term feelings will unsuccessful, eating and drinking without temperance, work and rest is not normal, causes depression of liver-QI, dysfunction of the spleen in transportation, gastral cavilty is become estranged, with the passing of time middle gas virtual loss, thus cause all symptoms.Should give determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs according to patient's practical situation clinically.Usually chronic gastritis is divided into following several: dyspepsia injures one's stomach, and type, spleen-stomach deficiency-cold, stomach-Yin deficiency, pathogenic heat are violated gastric pattern, stagnation of liver-QI is violated gastric pattern, the stagnant type that injures one's stomach of the stasis of blood, liver-fire invading the stomach type, the spleen and stomach being stranded by dampness type etc.
The scorching hot pain of stomach-Yin deficiency patient gastral cavilty, noisy discomfort, though famine and poor appetite, xerostomia is thirsty, defecates involved and abstruse, red tongue has crackle, the stripping of tongue fur light or few tongue, pulse condition stringy and thready pulse number.Card belongs to incoordination between the liver and spleen, stomach-Yin virtual loss, suitable soothing liver and strengthening spleen, tonifying YIN nourishing the stomach.
The Western medicine that general therapeutic is used has: atropine, probanthine, belladonna mixture etc.Gastric hyperacidity can be with the PPI proton pump inhibitor as rabeprazole, lansoprazole, omeprazole etc., and patients whose symptoms were less severe can be with the H2 receptor blocking agent as cimetidine, ranitidine, aluminium hydroxide amine etc.Achlorhydria or anacidity person can give 1% dilute hydrochloric acid or Pepsin Mixture, with dyspepsia person, can add with digestants such as pancreatin tablets, polyzyme tabletses.Gastric mucosa biopsy finds that the helicobacter pylori person adds antibiotic therapy.The obvious person of bile reflux can be wriggled to strengthen gastric antrum section with metoclopramide and motilium, reduces bile reflux.Hydrotalcite tablet, cholestyramine, sucralfate can be combined with bile acid, mitigation symptoms.
Because stomach-Yin deficiency patient is the five internal organs weaknesses, insufficiency of vital energy and blood causes serious symptom, if depress by force the disease disease such as pain with Western medicine, the five internal organs are not taken good care of, and only can cause disease day by day serious.Therefore, the chronic gastritis of this kind of symptom will be take the treatment by Chinese herbs effect as good.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition for the treatment of chronic periodontitis and gastritis;
Another object of the present invention is to provide a kind of Chinese medicine composition preparation method for the treatment of chronic periodontitis and gastritis.
The objective of the invention is to realize by following technical scheme:
The Chinese medicine composition of the described treatment chronic periodontitis of patent of the present invention and gastritis, it is to be prepared from by the raw material that comprises following weight portion:
Rhizoma Homalomenae 30-70 part, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) root 10-50 part, Herba Dichodrae root 20-60 part, Herba Cistanches 30-70 part, Ganoderma 10-40 part, Cordyceps 5-20 part, wild ginseng 5-20 part, Radix Pseudostellariae 5-20 part, Radix Fructus Rosae Laevigatae 30-70 part;
Preferably, be to be prepared from by the raw material that comprises following weight portion:
Rhizoma Homalomenae 40-60 part, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) root 15-40 part, Herba Dichodrae root 30-50 part, Herba Cistanches 40-60 part, Ganoderma 20-30 part, Cordyceps 8-15 part, wild ginseng 8-15 part, Radix Pseudostellariae 8-15 part, Radix Fructus Rosae Laevigatae 40-60 part;
More preferably, be to be prepared from by the raw material that comprises following weight portion:
50 parts of Rhizoma Homalomenaes, 20 parts of Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) roots, 35 parts of Herba Dichodrae roots, 50 parts of Herba Cistanches, 25 parts of Ganodermas, 10 parts of Cordyceps, 10 parts of wild ginsengs, 10 parts of Radix Pseudostellariaes, 50 parts of Radix Fructus Rosae Laevigataes.
Below crude drug source and the main effect of Chinese medicine preparation of the present invention:
Cordyceps: for section ergot fungus cordyceps sinensis bacterium Cordyeps sinensis (BerK.) Sace. colonizes in Stroma on the Hepialidae insect larvae and the dry composite body of larva corpse.The Gan Pingbao lung, for the deficiency of the lung or deficiency of both the lung and kidney.
Wild ginseng: the dry root of the wild product of Araliaceae Radix Ginseng Panax ginseng C. A. Mey..The effect that tonify deficiency emergency treatment of collapse, strongly invigorating primordial QI are arranged.
Radix Pseudostellariae: the dried root of pinkwort Radix Ginseng Pseudostellaria heterophylla (Miq.) Pax ex Pax et hoffm..Can mend strengthening spleen and lung, supplementing QI for promoting the production of body fluid.
Ganoderma: On Polyporaceae Ganoderma lucidum (Leyss. Ex Fr.) Karst. Ganoderna lucidum (Leyss.ex Fr.) Karst. or Ganoderma Ganoderna sinense Zhao, the dry sporophore of Xu et Zhang.Invigorating QI and tranquilization, replenishing and restoring lung-QI.
Herba Cistanches: the fleshy stem of the dry zone scale leaf of orobanchaceae plant cistanche Cistanche deserticola Y. C. Ma or Cistanche Tubulosa Cistanche tubulosa (Schrenk) Wight.Kidney-replenishing, benefiting essence-blood, loosening bowel to relieve constipation.
Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) root: be the dry root of Fumaraceae Corydalis Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) Corydalis saxicola Bunting.Function: heat-clearing and toxic substances removing, dampness removing, stable, dissipating blood stasis for subsidence of swelling, have antiinflammatory, function of gallbladder promoting, antiviral, sterilization, sedation and analgesia, enhancing immunologic function, antineoplastic action at analgesic hemostatic.
The Herba Dichodrae root: the Convolvulaceae Herba Dichodrae belongs to the dry root of Herba Dichodrae Dichondra repens.Heat clearing away; Dampness removing; Removing toxic substances.
Rhizoma Homalomenae: the dry rhizome of aroid Rhizoma Homalomenae Homalomena occulta (Lour.) Schott.There is the effects such as wind-damp dispelling, relaxing muscles and tendons and activating QI and blood in the collateral, pain relieving, detumescence.Cure mainly rheumatic arthralgia, stomachache, carbuncle skin ulcer swollen etc.
Radix Fructus Rosae Laevigatae: the dry root of rosaceous plant Fructus Rosae Laevigatae Rosa laevigata Michx..Can promoting blood circulation to remove blood stasis, the convergence of drawing out pus by applying a plaster to the affected part, dispel the wind that it is wet to drive.
Another aspect of the present invention has been to provide the preparation method of the active component of Chinese medicine composition of the present invention, the method be adopt the ethanol of water extraction or 40-90% concentration expressed in percentage by volume ultrasonic, backflow, lixiviate or/and percolation extract.Concrete its preparation method is as follows:
Scheme one: get whole 9 flavor medical materials, extracting in water 2-3 time, each amount of water is equivalent to 6-12 times of medical material gross weight, each extraction time is 1-3 hour, and merge extractive liquid, filters, filtrate is concentrated into the clear paste that 70-80 ℃ of lower relative density is 1.10-1.25, obtains active component.
Scheme two: get whole 9 flavor medical materials, extracting in water 2-3 time, each amount of water is equivalent to 6-12 times of medical material gross weight, each extraction time is 1-3 hour, merge extractive liquid,, filter, and filtrate is concentrated into the clear paste that 70-80 ℃ of lower relative density is 1.05-1.20, add ethanol, making containing the alcohol amount is 40-70%, and standing 12-24 hour, filter, the extractum that when filtrate is concentrated into 70-80 ℃, relative density is 1.10-1.25, obtain active component.
Scheme three: get whole 9 flavor medical materials, use ethanol ultrasonic extraction 3-4 time, add medical material gross weight 2-4 50-90% ethanol doubly at every turn, each supersound extraction 2-5 hour, filter merging filtrate, the extractum that while being concentrated into 70-80 ℃, relative density is 1.10-1.25, obtain active component.
Scheme four: get whole 9 flavor medical materials, use 40-80% alcohol reflux 2-3 time, the 4-10 that each ethanol consumption is the medical material total amount doubly, extraction time is 1-4 hour, and merge extractive liquid, filters, the extractum that when filtrate is concentrated into 60-80 ℃, relative density is 1.10-1.25, obtain active component.
Scheme five: get whole 9 flavor medical materials, add ethanol percolate extraction 3-4 time, add amount of alcohol to be equivalent to 1～2 times of medical material gross weight at every turn, concentration of alcohol counts 40%～60% with volume ratio, and percolation speed is that effluent per minute accounts for raw material gross weight 0.2%～0.6%, collects percolate, reclaim ethanol, be evaporated to 1～2 times that is equivalent to the medical material gross weight, filter, obtain active component.
Chinese medicine composition of the present invention can be made various common formulations together by its effective ingredient and/or pharmaceutically acceptable carrier, as tablet, capsule, pill, drop pill, granule, medicinal tea, mixture, syrup, powder etc.
Pharmaceutically acceptable carrier of the present invention includes but not limited to following:
Filler: lactose, dextrin, Icing Sugar, calcium sulfate, sucrose, mannitol, microcrystalline Cellulose, glucose, corn starch etc.
Binding agent: starch slurry, pregelatinized Starch, dextrin etc.
Disintegrating agent: starch, carboxymethyl starch sodium, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, low replacement-carboxy-propyl cellulose, citric acid, polyoxyethylene sorbitan monoleate etc.
Lubricant: stearic acid, calcium stearate, magnesium stearate, Pulvis Talci, hydrogenated vegetable oil, Polyethylene Glycol, sodium lauryl sulphate, glyceryl monostearate etc.
Wetting agent: distilled water, ethanol etc.
Correctives: sucrose, stevioside, aspartame etc.
Cosolvent: the polyhydric alcohol such as glycerol, sorbitol.
Fluidizer: micropowder silica gel, Pulvis Talci etc.
Antiseptic: benzoic acid, sodium benzoate, sorbic acid and salt thereof, propanoic acid, parabens etc.
The sugar coating material, as sucrose, Pulvis Talci, gelatin, pigment, river wax etc.; Thin film coating material, as stomach dissolution type water, pure coating material etc.
For example, it can be prepared as various common dosage forms by one of following method: tablet, capsule, pill, drop pill, medicinal tea, mixture, syrup, powder
Method 1: granule
Get scheme one to one of scheme five gained active component, add granule to commonly use adjuvant, production method is prepared into the granule of Chinese medicine composition of the present invention routinely.
Above-mentioned granule adjuvant commonly used comprises one of filler, binding agent, lubricant or whole.
Method 2: syrup
Get scheme one to one of scheme five gained active component, add syrup to commonly use adjuvant, production method is prepared into the syrup of Chinese medicine composition of the present invention routinely.
Above-mentioned syrup adjuvant commonly used comprises one of correctives, antiseptic, cosolvent or whole.
Method 3: tablet
Get scheme one to one of scheme five gained active component, add tablet to commonly use adjuvant, production method is prepared into the tablet of Chinese medicine composition of the present invention routinely.
Above-mentioned tablet adjuvant commonly used comprises one of filler, binding agent, disintegrating agent, lubricant or whole.
Method 4: capsule
Get scheme one to one of scheme five gained active component, add capsule to commonly use adjuvant, production method is prepared into the capsule of Chinese medicine composition of the present invention routinely.
Above-mentioned capsule adjuvant commonly used comprises one of filler, fluidizer, disintegrating agent, lubricant or whole.
The spleen is in charge of sending up essential substances, the stomach being liable to sending digested food downward, and one rise and one drop completes transporting and the defeated cloth of diet jointly.Under pathological conditions, spleen the lucid yang sending up stomach the turbid descending not not often, stomach is the turbid descending spleen the lucid yang sending up not not, and the two is mutually normal because sick.Spleen is source of generating QI and blood, the strong the source of vital function foot of transporting of temper, and deficiency-weakness of spleen-QI, transporting is unable, the hemopoietic deficiency, internal organs lose supports, a little less than insufficiency of the spleen blood.Insufficiency of the spleen transporting mistake department, cause retention of water-damp in the body.Cold-damp disturbing the spleen, insufficiency of the spleen can not win wet, light turbid damp obstructing in middle-JIAO, for expectorant is drink, very water is wet stops holding or overflowing skin, for swelling as swollen.Weakness of the spleen and stomach, directly cause stomach-QI being unable to descend normally.Insufficiency of stomach is not received, and is received, wears down, the digesting food hypofunction.A little less than insufficiency of stomach-QI, cold originating from the interior.The cold-evil violates stomach, and damage stomach sun often turns to main pathological manifestations with QI stagnated by cold with losing in temperature.QI stagnated by cold, lose in temperature and lead to, stagnation of QI and blood may bring about pain.This is chronic gastritis due to the middle empty stagnation of QI, belongs to deficiency syndrome, cold, the stagnation of QI often held concurrently, phlegm-damp.
Suffer from a deficiency of the kidney thanks to cloudy, the moon is not contained sun, causes hyperactivity of deficient fire, therefore though see that fire rises sign, is caused by the deficiency of YIN in fact.The arteries and veins that asthenic fire foot sun is bright, under follow nose and enter outward in upper tooth, also go out to hold under the arm the choma lip.Asthenic fire is followed through upper punch, the floating pain of root of the tooth pine, and traction and brain, or see that the lip cheek swells and ache, red swelling of gingiva festers, gingival atrophy is hemorrhage, the chronic periodontitis that this causes for weakness of the spleen and stomach.
The applicant on the basis of research tradition Chinese herbal medicine, through test for many years, found to by the chronic periodontitis that causes of the empty stagnation of QI and the good several drugs of chronic gastritis therapeutic effect and completed the present invention.
In Chinese medicine composition of the present invention, the Rhizoma Homalomenae cold-damp in spleen of dispelling; The Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) root enters the stomach warp, eliminating stasis to stop pain, Anhydroalkannin sterilization, the sense of discomfort that amelioration of inflammation causes rapidly; Herba Dichodrae root eliminating damp, detoxifying, make water liquid be able to transporting; The Herba Cistanches kidney-replenishing, warm blood vessels, circulation qi-blood-body fluid; The Ganoderma invigorating QI and tranquilization, replenishing and restoring lung-QI, control asthenia and lose heart; The Cordyceps kidney tonifying, mend marrow, control suffer from a deficiency of the kidney, kidney-replenishing; Wild ginseng tonify deficiency emergency treatment of collapse, strongly invigorating primordial QI; Radix Pseudostellariae is mended strengthening spleen and lung, supplementing QI for promoting the production of body fluid; Radix Fructus Rosae Laevigatae promoting blood circulation to remove blood stasis, the convergence of drawing out pus by applying a plaster to the affected part, dispel the wind that it is wet to drive.Above all medicines share, can warm spleen soil, and water paddy transfers as cloudy essence, changes essence for blood again, makes the strong fortune of temper, and water is wet not to stop to hold, and gastric qi is logical, and to fall behavior suitable, and phlegm retention, water is wet, the stasis of blood is turbid etc., and disease is eliminated, and yang-energy is given birth to, and gastritis, periodontitis show effect no longer repeatedly, are fully recovered.
A kind of Chinese medicine composition for the treatment of chronic periodontitis and gastritis provided by the invention has the following advantages:
1, the present invention to because of in due to the empty stagnation of QI chronic periodontitis and gastritis significant curative effect is arranged.
2, the present invention treats chronic periodontitis and compares with metronidazole, and curative effect is better, is not substantially having side effects.Simple metronidazole treatment lacks effective measures aspect enhancing body whole body ability of regulation and control, chronic periodontitis with suffer from a deficiency of the kidney and damp and hot pathogenic factor invasion and attack relevant, the present invention can treat from inside to outside by inflammation under clearing away heat and eliminating dampness, the kidney invigorating, thereby disease disease is effected a radical cure, evident in efficacy.
3, the present invention compares with SANJIU WEITAI KELI, and curative effect is better, has significant difference.A little less than the present invention is directed to insufficiency of stomach-QI, the chronic gastritis that the cold originating from the interior class cause of disease has guided, can change cold pleasant, stomach function regulating removing dampness, invigorating the spleen and stomach, promoting blood circulation and stopping pain, thereby can effectively treat the chronic gastritis that the stomach-Yin virtual loss causes.
The specific embodiment
Further illustrate the present invention below by embodiment.It should be understood that embodiments of the invention are for the present invention rather than limitation of the present invention are described.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the scope of protection of present invention.Except as otherwise noted, the percent of the amount of alcohol in the present invention is percentage by volume, and v/v means the volume ratio of solution.
embodiment 1: the preparation of granule (scheme one)
Get 50 parts of Rhizoma Homalomenaes, 20 parts of Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) roots, 35 parts of Herba Dichodrae roots, 50 parts of Herba Cistanches, 25 parts of Ganodermas, 10 parts of Cordyceps, 10 parts of wild ginsengs, 10 parts of Radix Pseudostellariaes, 50 parts of Radix Fructus Rosae Laevigataes, extracting in water 3 times, three amount of water are respectively 12 times, 8 times, 6 times of medical material gross weight, three extraction times are respectively 3 hours, 2 hours, 1 hour, merge extractive liquid,, filter, filtrate is concentrated into the clear paste that 80 ℃ of lower relative densities are 1.10, add cane sugar powder, dextrin, mix, granulation, dry, granulate, packing, obtain.
embodiment 2: the preparation of granule (scheme four)
Get 30 parts of Rhizoma Homalomenaes, 10 parts of Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) roots, 20 parts of Herba Dichodrae roots, 30 parts of Herba Cistanches, 10 parts of Ganodermas, 5 parts of Cordyceps, 5 parts of wild ginsengs, 5 parts of Radix Pseudostellariaes, 30 parts of Radix Fructus Rosae Laevigataes, with 40% alcohol reflux 3 times, each ethanol consumption is respectively 10 times, 8 times, 4 times of medical material total amount, 4 hours, 2 hours, 1 hour respectively extraction time, merge extractive liquid,, filter, the extractum that when filtrate is concentrated into 60 ℃, relative density is 1.25, obtain active component, add lactose, starch, granulation, drying, granulate, packing, obtain.
embodiment 3: the preparation of syrup (scheme two)
Get 70 parts of Rhizoma Homalomenaes, 50 parts of Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) roots, 60 parts of Herba Dichodrae roots, 70 parts of Herba Cistanches, 40 parts of Ganodermas, 20 parts of Cordyceps, 20 parts of wild ginsengs, 20 parts of Radix Pseudostellariaes, 70 parts of Radix Fructus Rosae Laevigataes, extracting in water 3 times, three amount of water are equivalent to respectively 12 times of medical material gross weight, 8 times, 6 times, 3 hours respectively each extraction time, 2 hours, 1 hour, merge extractive liquid, filter, filtrate is concentrated into the clear paste that 70 ℃ of lower relative densities are 1.20, add ethanol, making containing the alcohol amount is 40%, standing 24 hours, filter, the extractum that when filtrate is concentrated into 80 ℃, relative density is 1.10, add sucrose, potassium sorbate, mix, packing, obtain.
embodiment 4: the preparation of syrup (scheme five)
Get 40 parts of Rhizoma Homalomenaes, 15 parts of Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) roots, 30 parts of Herba Dichodrae roots, 40 parts of Herba Cistanches, 20 parts of Ganodermas, 8 parts of Cordyceps, 8 parts of wild ginsengs, 8 parts of Radix Pseudostellariaes, 40 parts of Radix Fructus Rosae Laevigataes, add ethanol percolate extraction 4 times, add amount of alcohol to be equivalent to respectively 2 times of medical material gross weights at every turn, 2 times, 1 times, 1 times, four times percolation is respectively 60% with concentration of alcohol, 50%, 40%, 40%, four percolation speed are respectively effluent per minute and account for 0.2% of raw material gross weight, 0.3%, 0.4%, 0.6%, collect percolate, reclaim ethanol, be evaporated to 1 times that is equivalent to the medical material gross weight, filter, add glycerol, nipalgin, stevioside, mix, packing, obtain.
embodiment 5: the preparation of tablet (scheme three)
Get 60 parts of Rhizoma Homalomenaes, 40 parts of Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) roots, 50 parts of Herba Dichodrae roots, 60 parts of Herba Cistanches, 30 parts of Ganodermas, 15 parts of Cordyceps, 15 parts of wild ginsengs, 15 parts of Radix Pseudostellariaes, 60 parts of Radix Fructus Rosae Laevigataes, with ethanol ultrasonic extraction 4 times, add respectively 4 times of medical material gross weights for four times, 3 times, 2 times, 2 times, four times ultrasonic is respectively 90% with concentration of alcohol, 80%, 60%, 50%, four supersound extraction times are respectively 5 hours, 4 hours, 3 hours, 2 hours, extracting liquid filtering, merging filtrate, the extractum that while being concentrated into 70 ℃, relative density is 1.25, add lactose, Pulvis Talci, mix, granulate, dry, tabletting, obtain.
embodiment 6: the preparation of tablet (scheme two)
Get 30 parts of Rhizoma Homalomenaes, 50 parts of Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) roots, 20 parts of Herba Dichodrae roots, 70 parts of Herba Cistanches, 10 parts of Ganodermas, 20 parts of Cordyceps, 5 parts of wild ginsengs, 20 parts of Radix Pseudostellariaes, 30 parts of Radix Fructus Rosae Laevigataes, extracting in water 2 times, each amount of water is equivalent to respectively 12 times of medical material gross weight, 10 times, each extraction time is respectively 3 hours, 2 hours, merge extractive liquid, filter, filtrate is concentrated into the clear paste that 80 ℃ of lower relative densities are 1.05, add ethanol, making containing the alcohol amount is 70%, standing 12 hours, filter, the extractum that when filtrate is concentrated into 70 ℃, relative density is 1.25, add dextrin, magnesium stearate, microcrystalline Cellulose, mix, granulate, dry, tabletting, obtain.
embodiment 7: the preparation of capsule (scheme four)
Get 70 parts of Rhizoma Homalomenaes, 10 parts of Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) roots, 60 parts of Herba Dichodrae roots, 30 parts of Herba Cistanches, 40 parts of Ganodermas, 5 parts of Cordyceps, 20 parts of wild ginsengs, 5 parts of Radix Pseudostellariaes, 70 parts of Radix Fructus Rosae Laevigataes, with alcohol reflux 2 times, each concentration of alcohol is respectively 80%, 60%, each ethanol consumption is respectively 10 times of medical material total amount, 8 times, extraction time is respectively 4 hours, 3 hours, merge extractive liquid, filter, the extractum that when filtrate is concentrated into 80 ℃, relative density is 1.10, add micropowder silica gel, carboxymethyl starch sodium, mix, granulate, dry, sieve, enter capsule, obtain.
embodiment 8: the preparation of capsule (scheme five)
Get 40 parts of Rhizoma Homalomenaes, 40 parts of Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) roots, 30 parts of Herba Dichodrae roots, 60 parts of Herba Cistanches, 20 parts of Ganodermas, 15 parts of Cordyceps, 8 parts of wild ginsengs, 15 parts of Radix Pseudostellariaes, 40 parts of Radix Fructus Rosae Laevigataes, add ethanol percolate extraction 3 times, add amount of alcohol to be equivalent to 2 times of medical material gross weights at every turn, 2 times, 1 times, three times percolation is respectively 60% with concentration of alcohol, 50%, 40%, percolation speed is that effluent per minute accounts for raw material gross weight 0.2%～0.6%, collect percolate, reclaim ethanol, be evaporated to 2 times that are equivalent to the medical material gross weight, filter, add Polyethylene Glycol, starch, Pulvis Talci, mix, granulate, dry, sieve, enter capsule, obtain.
?
clinical treatment is summed up
One, chronic periodontitis clinical summary
1 diagnostic criteria: Ministry of Public Health " about the regulation of dental caries periodontal disease national statistics investigation " carries out the oral cavity routine examination to the patient, with the check result of 6 section index teeth in oral cavity, means this section periodontal health situation.The examination of mouth content comprises gingival atrophy, gingival hemorrhage, dental calculus and periodontal pocket situation.
2 medicines
Treatment group: take embodiment 5 tablets, 3 times on the one, each 2.
Matched group: Metronidazole Tablet 0.2g, 3 times on the one.
3 clinical groupings
Treatment group: 40 examples, male 25 examples wherein, female's 15 examples, 43.3 ± 8.4 years old age.
Matched group: 38 examples, male 20 examples wherein, female's 18 examples.43.0 ± 7.9 years old age.
There are no significant poor (P>0.05) at aspects such as age, sex, the courses of disease for treatment group and matched group, has comparability.
4 observed results
4.1 criterion of therapeutical effect
Recovery from illness: the gingiva color and luster is normal, and without periodontal pocket, gingival edge is without secretions, and tooth is not loosening, and it is normal that masticatory function is recovered, transference cure;
Take a turn for the better: gingivitis disappears, and without hemorrhage, periodontal pocket shoals, and odontoseisis is clearly better, and masticatory function is obviously improved, and symptom is clearly better;
Invalid: symptom is without improving or increasing the weight of.
The cardinal symptom integration: heavy (+++), in (++), light (+), each "+" is 1 minute, transference cure is 0 minute.
4.2 therapeutic outcome is in Table 1.
Table 1 liang group Clinical efficacy comparison
| Group | Number of cases | Cure | Take a turn for the better | Invalid | Effective percentage |
| Treatment group | 40 | 28 | 9 | 3 | 92.50% * |
| Matched group | 38 | 17 | 10 | 11 | 71.05% |
Annotate: compare * P<0.05 with the matched group effective percentage.
Table 2 liang group clinical symptoms integral contrast (
)
Annotate: compare * P<0.05 with matched group; With front relatively △ P<0.05 for the treatment of.
Table 1, table 2 result show: after treatment group, treatment of control group, the state of an illness all is improved (P<0.05), and treatment group is compared with the effect after treatment of control group, has notable difference (P<0.05).
Result shows: Chinese medicine composition provided by the invention has the effect for the treatment of chronic periodontitis, under the condition substantially do not had side effects, with the Western medicine group, compares, and curative effect is better.Simple metronidazole treatment lacks effective measures aspect enhancing body whole body ability of regulation and control, chronic periodontitis with suffer from a deficiency of the kidney and damp and hot pathogenic factor invasion and attack relevant, the present invention can treat from inside to outside by inflammation under clearing away heat and eliminating dampness, the kidney invigorating, thereby disease disease is effected a radical cure, evident in efficacy.
?
Two, chronic gastritis clinical summary
1 diagnostic criteria: " new Chinese medicine guideline of clinical investigations " reaches " Chinese Internal Medicine ".Diagnostic point is:
Primary symptom: gastralgia, the abdominal distention poor appetite, defecate not smooth, and tongue is red, yellow and greasy fur, lack of appetite is indigestion and loss of appetite;
Inferior disease: meet angry or nervous recurrence or increase the weight of, acid regurgitation Yuan gas, feel sick, and mouth is sticky, sees the erosion of mucosa congestion and edema and petechia under gastroscope; See in biopsy specimen that on spleen, cell infiltration appears in Intradermal.
Exclusion standard: chronic atrophic gastritis, the digestive tract organic disease persons such as esophagus, Stomach duodenum ulcer, tumor, liver, gallbladder, pancreas; Suffer from severe cardiac, lung, kidney and hemopoietic system disease patient; Diabetics; Allergic constitution and can not coordinate the examiner, medication or data are not congruent in accordance with regulations affects the treatment and safety judgement person.
2 medicines
Treatment group: take embodiment 3 syrups, 3 times on the one, each 10ml.
Matched group: SANJIU WEITAI KELI (Sanjiu Pharmaceutical Co., Ltd), every day 3 times, each 1 bag.
3 clinical groupings
Treatment group: 40 examples, male 25 examples wherein, female's 15 examples, 43.3 ± 8.4 years old age.
Matched group: 38 examples, male 20 examples wherein, female's 18 examples.43.0 ± 7.9 years old age.
There are no significant poor (P>0.05) at aspects such as age, sex, the courses of disease for treatment group and matched group, has comparability.
4 observed results
4.1 criterion of therapeutical effect
Observation is with main clinic symptoms such as gastralgia, abdominal distention poor appetite, stool are not smooth, acid regurgitation Yuan gas, feel sick, the clinical minor symptoms such as mouth is sticky, emotional factors impact, according to the conditions of patients degree, minute without, light, weigh three kinds of degree, remember respectively 1,2,3 minute, picture of the tongue and pulse condition only as a reference, are not participated in integral and calculating; Cardinal symptom and minor symptom integration add up to total mark; The state of an illness is heavier, and scoring is higher, gastroscopy Active inflammation scope, gastric mucosa congestion, edema sign, and pathologic finding inflammatory infiltration sign.
Recovery from illness: sign disappears or basic the disappearance;
Produce effects: sign is obviously improved, and symptom is clearly better;
Invalid: symptom is without improving or increasing the weight of.
4.2 therapeutic outcome is in Table 1.
Table 1 liang group Clinical efficacy comparison
| Group | Number of cases | Cure | Take a turn for the better | Invalid | Effective percentage |
| Treatment group | 50 | 23 | 23 | 4 | 92.50% * |
| Matched group | 50 | 13 | 26 | 11 | 81.05% |
Annotate: compare * P<0.05 with the matched group effective percentage.
Clinical effectiveness shows: Chinese medicine composition provided by the invention has the effect for the treatment of chronic gastritis, under the condition substantially do not had side effects, with matched group, compares, and curative effect is better.We cure mainly disease for etiology and pathogenesis be insufficiency of stomach-QI a little less than, cold originating from the interior, often with QI stagnated by cold with lose in temperature and turn to main pathological manifestations, the present invention can change cold pleasant, stomach function regulating removing dampness, invigorating the spleen and stomach, promoting blood circulation and stopping pain, thereby can effectively treat the chronic gastritis that the stomach-Yin virtual loss causes.
?
model case
Lee, female, 26 years old.Congested redness appears in the private prosecution gingiva, odontoseisis, yellowish fur, red tongue, pulse condition stringy and rapid pulse.Syndrome differential diagnosis is the type of yin deficiency chronic periodontitis of suffering from a deficiency of the kidney.Take the embodiment of the present invention 6 tablets, each 2, every day 3 times.After taking three days, the gingiva congestive symptom alleviates to some extent, and odontoseisis is clearly better.After taking continuously 14 days, masticatory function is recovered the normal teeth gingival inflammation and is disappeared, and tooth is not loosening.
What certain, man, 22 years old.Readme gingival swelling and pain, gingival hemorrhage, pain one week, takes the Western medicine pain relieving and slightly take a favorable turn, but drug withdrawal recurs.Check: the lip cheek swells and ache, and red swelling of gingiva festers.Dialectical being diagnosed as, the chronic periodontitis that weakness of the spleen and stomach causes.Take the embodiment of the present invention 4 syrups, each 10ml, every day 3 times.Take bleeding after a week and disappear, swelling reduces, pain relief.After being used in conjunction two weeks, pain disappears, and it is normal that masticatory function is recovered, and rechecks transference cure, is judged as recovery from illness.
Beam, man, 48 years old.Repeatedly show effect epigastric distending pain 3 years of private prosecution, played sx↑ last week, and singultus arranged, with after eating for very, once took ranitidine etc., poor effect.Examine see that tongue is dark red, white and thin fur, stringy pulse, dialectical is stagnation of QI causing retention of food, weakness of the spleen and stomach, stomach-QI being unable to descend normally.Take the embodiment of the present invention 1 granule, each 10g, 3 times on the one.After taking 7 days, symptom is clearly better, then takes 1 month, transference cure, and gastroscopy, without pathological changes performance, recovery from illness.
Lee, female, 51 years old.Have a stomach-ache more than 5 years, dry mouth dry tongue, decreased food intake are indigestion and loss of appetite, red tongue with yellow fur, stringy pulse and tight.Syndrome differential diagnosis is deficiency of stomach-Yin, yin collaterals damage, Deficiency and coldness of spleen and stomach.Take the embodiment of the present invention 8 capsules, each 2, every day 3 times, after taking 10 days, take a favorable turn, diet multiplication, pain relief.After serveing on February, transference cure, check ulcer disappears, and is judged to recovery from illness.
Although, above used general explanation, the specific embodiment and test, the present invention is described in detail, on basis of the present invention, can make some modifications or improvements it, and this will be apparent to those skilled in the art.Therefore, these modifications or improvements, all belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (9)
1. a Chinese medicine composition for the treatment of chronic periodontitis and gastritis is characterized in that it is to be prepared from by the raw material that comprises following weight portion:
Rhizoma Homalomenae 30-70 part, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) root 10-50 part, Herba Dichodrae root 20-60 part, Herba Cistanches 30-70 part, Ganoderma 10-40 part, Cordyceps 5-20 part, wild ginseng 5-20 part, Radix Pseudostellariae 5-20 part, Radix Fructus Rosae Laevigatae 30-70 part.
2. Chinese medicine composition according to claim 1 is characterized in that it is to be prepared from by the raw material that comprises following weight portion:
Rhizoma Homalomenae 40-60 part, Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) root 15-40 part, Herba Dichodrae root 30-50 part, Herba Cistanches 40-60 part, Ganoderma 20-30 part, Cordyceps 8-15 part, wild ginseng 8-15 part, Radix Pseudostellariae 8-15 part, Radix Fructus Rosae Laevigatae 40-60 part.
3. Chinese medicine composition according to claim 1 is characterized in that it is to be prepared from by the raw material that comprises following weight portion:
50 parts of Rhizoma Homalomenaes, 20 parts of Corydalis thalictrifolia Franch. (Radix Corydalis Thalictrifoliae) roots, 35 parts of Herba Dichodrae roots, 50 parts of Herba Cistanches, 25 parts of Ganodermas, 10 parts of Cordyceps, 10 parts of wild ginsengs, 10 parts of Radix Pseudostellariaes, 50 parts of Radix Fructus Rosae Laevigataes.
4. according to any one described Chinese medicine composition of claim 1-3, it is characterized in that its active component is prepared from by the following method:
Get whole 9 flavor medical materials, extracting in water 2-3 time, each amount of water is equivalent to 6-12 times of medical material gross weight, each extraction time is 1-3 hour, and merge extractive liquid, filters, filtrate is concentrated into the clear paste that 70-80 ℃ of lower relative density is 1.10-1.25, obtains active component.
5. according to any one described Chinese medicine composition of claim 1-3, it is characterized in that its active component is prepared from by the following method:
Get whole 9 flavor medical materials, extracting in water 2-3 time, each amount of water is equivalent to 6-12 times of medical material gross weight, each extraction time is 1-3 hour, merge extractive liquid,, filter, and filtrate is concentrated into the clear paste that 70-80 ℃ of lower relative density is 1.05-1.20, add ethanol, making containing the alcohol amount is 40-70%, and standing 12-24 hour, filter, the extractum that when filtrate is concentrated into 70-80 ℃, relative density is 1.10-1.25, obtain active component.
6. according to any one described Chinese medicine composition of claim 1-3, it is characterized in that its active component is prepared from by the following method:
Get whole 9 flavor medical materials, use ethanol ultrasonic extraction 3-4 time, add medical material gross weight 2-4 50-90% ethanol doubly at every turn, each supersound extraction 2-5 hour, filter merging filtrate, the extractum that while being concentrated into 70-80 ℃, relative density is 1.10-1.25, obtain active component.
7. according to any one described Chinese medicine composition of claim 1-3, it is characterized in that its active component is prepared from by the following method:
Get whole 9 flavor medical materials, use 40-80% alcohol reflux 2-3 time, the 4-10 that each ethanol consumption is the medical material total amount doubly, extraction time is 1-4 hour, and merge extractive liquid, filters, the extractum that when filtrate is concentrated into 60-80 ℃, relative density is 1.10-1.25, obtain active component.
8. according to any one described Chinese medicine composition of claim 1-3, it is characterized in that its active component is prepared from by the following method:
Get whole 9 flavor medical materials, add ethanol percolate extraction 3-4 time, add amount of alcohol to be equivalent to 1～2 times of medical material gross weight at every turn, concentration of alcohol counts 40%～60% with volume ratio, and percolation speed is that effluent per minute accounts for raw material gross weight 0.2%～0.6%, collects percolate, reclaim ethanol, be evaporated to 1～2 times that is equivalent to the medical material gross weight, filter, obtain active component.
9. a Chinese medicine preparation for the treatment of chronic periodontitis and gastritis, comprise treatment chronic periodontitis and the Chinese medicine composition of gastritis and the pharmaceutically acceptable carrier of any one in claim 1～3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310425402.1A CN103479824B (en) | 2013-09-18 | 2013-09-18 | A kind ofly treat Chinese medicine composition of chronic periodontitis and gastritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310425402.1A CN103479824B (en) | 2013-09-18 | 2013-09-18 | A kind ofly treat Chinese medicine composition of chronic periodontitis and gastritis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103479824A true CN103479824A (en) | 2014-01-01 |
| CN103479824B CN103479824B (en) | 2015-08-19 |
Family
ID=49820637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310425402.1A Active CN103479824B (en) | 2013-09-18 | 2013-09-18 | A kind ofly treat Chinese medicine composition of chronic periodontitis and gastritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103479824B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796878A (en) * | 2016-03-24 | 2016-07-27 | 吕隆鲲 | Traditional Chinese medicine for treating yin and blood deficiency type periodontitis |
| CN106109778A (en) * | 2016-07-28 | 2016-11-16 | 佳木斯大学 | Chinese medicine composition for the treatment of periodontitis and its preparation method and application |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586560A (en) * | 2004-07-07 | 2005-03-02 | 香港养春堂中药有限公司 | Cordyceps, ginseng, pilose antler and fleece-flower root life-prolonging pill |
| CN101703730A (en) * | 2009-11-06 | 2010-05-12 | 邓仁清 | Health care wine made of ginseng and the like |
-
2013
- 2013-09-18 CN CN201310425402.1A patent/CN103479824B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1586560A (en) * | 2004-07-07 | 2005-03-02 | 香港养春堂中药有限公司 | Cordyceps, ginseng, pilose antler and fleece-flower root life-prolonging pill |
| CN101703730A (en) * | 2009-11-06 | 2010-05-12 | 邓仁清 | Health care wine made of ginseng and the like |
Non-Patent Citations (2)
| Title |
|---|
| 唐存雄: "中医治疗慢性萎缩性胃炎近况", 《广西中医药》, vol. 20, no. 6, 31 December 1997 (1997-12-31) * |
| 章立群；等: "肾虚胃热型慢性牙周炎的中西医结合治疗研究", 《当代医学》, vol. 17, no. 10, 30 April 2011 (2011-04-30), pages 159 - 160 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105796878A (en) * | 2016-03-24 | 2016-07-27 | 吕隆鲲 | Traditional Chinese medicine for treating yin and blood deficiency type periodontitis |
| CN106109778A (en) * | 2016-07-28 | 2016-11-16 | 佳木斯大学 | Chinese medicine composition for the treatment of periodontitis and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103479824B (en) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103272169B (en) | Application of rhodiola rosea compound composite in treating erosive gastritis | |
| CN103751739B (en) | The Chinese medicine composition for the treatment of chronic gastritis, its application in the medicine of preparation treatment chronic gastritis and preparation method thereof | |
| CN101874874A (en) | Chinese medicinal preparation for treating helicobacter pylori concerned chronic gastritis and preparation method thereof | |
| CN102205107A (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN103385993B (en) | Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
| CN104324125B (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof | |
| CN103479824B (en) | A kind ofly treat Chinese medicine composition of chronic periodontitis and gastritis and preparation method thereof | |
| CN105535511A (en) | Stomach harmonizing and pain relieving granule and preparation method thereof | |
| CN105535495A (en) | Chinese medicinal composition for treating esophageal cancer by reinforcing vital essence and strengthening primordial qi and preparation method | |
| CN105214032A (en) | The solid dispersion tablet for the treatment of peptic ulcer | |
| CN104548029A (en) | Pharmaceutical composition for treating epigastric pain | |
| CN102614344B (en) | Traditional Chinese medicine for treating qi-blood deficiency periodontitis, preparation method and administration method thereof | |
| CN111329959A (en) | Compound traditional Chinese medicine for intervening gastric cancer infiltration and metastasis and preparation method thereof | |
| CN105250946A (en) | Solid dispersion for treating peptic ulcers | |
| CN105214035A (en) | One treats peptic ulcer tablet and preparation method thereof | |
| CN104173598A (en) | Composition for treating gastritis and peptic ulcer and preparation method thereof | |
| CN100333777C (en) | Medicine for improving enterogastric function after radiation chemiotherapy | |
| CN102008520A (en) | Drug for preventing and treating chronic mountain sickness and preparation method thereof | |
| JPS5813518A (en) | Preparation of drug consisting of ganoderma lucidum and elfvingia applanata | |
| CN105169199A (en) | Traditional Chinese medicinal composition for treating functional dyspepsia with syndrome of liver-stomach disharmony | |
| CN100335111C (en) | Medicine for rheumatism and its preparation | |
| CN105194608A (en) | Micro-powder capsule for treating peptic ulcers | |
| CN105168847A (en) | Traditional Chinese medicine for treating helicobacter pylori infected peptic ulcer | |
| CN103720827B (en) | A kind of Chinese medicine composition treating chronic superficial gastritis and preparation method thereof | |
| CN105250951A (en) | Preparing method for medicine for treating peptic ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160825 Address after: 21 No. 2116, 1 Times Building, No. 530012, national Avenue, the Guangxi Zhuang Autonomous Region, Nanning Patentee after: Guangxi Nanning yingnuo Intellectual Property Consulting Co. Ltd. Address before: 537700 Yulin Lu Chuan Hospital of traditional Chinese medicine, the Guangxi Zhuang Autonomous Region, China Patentee before: Feng Risheng |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160919 Address after: 537300 Guigang City, Pingnan County, Pingnan County, the Guangxi Zhuang Autonomous Region Patentee after: Institute of scientific and technical information, Pingnan County Address before: 21 No. 2116, 1 Times Building, No. 530012, national Avenue, the Guangxi Zhuang Autonomous Region, Nanning Patentee before: Guangxi Nanning yingnuo Intellectual Property Consulting Co. Ltd. |